Lipocine (NASDAQ:LPCN – Get Free Report) and Siga Technologies (NASDAQ:SIGA – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, valuation and risk.
Institutional and Insider Ownership
9.1% of Lipocine shares are owned by institutional investors. Comparatively, 55.4% of Siga Technologies shares are owned by institutional investors. 6.4% of Lipocine shares are owned by insiders. Comparatively, 2.0% of Siga Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Analyst Ratings
This is a summary of recent ratings and price targets for Lipocine and Siga Technologies, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lipocine | 1 | 1 | 0 | 1 | 2.33 |
| Siga Technologies | 1 | 0 | 0 | 0 | 1.00 |
Profitability
This table compares Lipocine and Siga Technologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Lipocine | -487.00% | -59.30% | -53.37% |
| Siga Technologies | 24.61% | 11.25% | 9.98% |
Earnings and Valuation
This table compares Lipocine and Siga Technologies”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Lipocine | $1.98 million | 9.45 | -$9.63 million | ($1.69) | -1.38 |
| Siga Technologies | $94.57 million | 3.52 | $23.28 million | $0.31 | 14.97 |
Siga Technologies has higher revenue and earnings than Lipocine. Lipocine is trading at a lower price-to-earnings ratio than Siga Technologies, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Lipocine has a beta of 0.5, indicating that its share price is 50% less volatile than the S&P 500. Comparatively, Siga Technologies has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500.
Summary
Siga Technologies beats Lipocine on 9 of the 14 factors compared between the two stocks.
About Lipocine
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.
About Siga Technologies
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.
Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.
